WO2024209429 - T CELLS FOR USE IN TREATING RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
National phase entry is expected:
Publication Number
WO/2024/209429
Publication Date
10.10.2024
International Application No.
PCT/IB2024/053367
International Filing Date
05.04.2024
Title **
[English]
T CELLS FOR USE IN TREATING RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
[French]
LYMPHOCYTES T DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉCIDIVANTE OU RÉFRACTAIRE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-chome
Chuo-ku
Osaka-shi, Osaka 541-0045, JP
Inventors
ABIKOFF, Cori
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
ATKURI, Kondala
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
LIU, Yue
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
Priority Data
63/457,937
07.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2540 | |
| EPO | Filing, Examination | 27858 | |
| Japan | Filing | 538 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 11435 |
Total: 42946 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides, among other things, methods for treating relapsed or refractory acute myeloid leukemia by administering to a subject in need thereof a therapeutically effective amount of an allogeneic composition comprising VDelta1+ (Vδ1+) gamma delta (γδ) T cells such that one or more symptoms or biomarkers is improved after treatment. The present disclosure also provides suitable doses of compositions comprising allogeneic Vδ1+gamma delta (γδ) T cells for administration to a subject suffering from relapsed or refractory AML. In some embodiments, the Vδ1+gamma delta (γδ) T cells are untransduced.[French]
La présente divulgation concerne, entre autres, des méthodes de traitement de la leucémie myéloïde aiguë récidivante ou réfractaire par administration à un sujet qui en a besoin d'une quantité thérapeutiquement efficace d'une composition allogénique comprenant des lymphocytes T VDelta1+ (Vδ1+) gamma delta (γδ) de telle sorte qu'un ou plusieurs symptômes ou biomarqueurs sont améliorés après traitement. La présente divulgation concerne également des doses appropriées de compositions comprenant des lymphocytes T allogéniques Vδ1+gamma delta (γδ) pour une administration à un sujet souffrant de LMA récidivante ou réfractaire. Dans certains modes de réalisation, les lymphocytes Vδ1+gamma delta (γδ) sont non transduits.